Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Added Value of Fine-Needle Aspiration (FNA) or Breast Magnetic Resonance Imaging (MRI) as Part of the "Triple Test" to Assess Palpable Abnormalities on a Breast Exam With Negative Imaging Findings.

    Jul 28, 2025DOI: 10.1245/s10434-025-17847-zJournal ArticleASO

    Written by: Jacqueline SlobinGrace TraversJoan PerezVictoria CollinsChristine ChenElisa PortJennifer L Marti

    Find these authors on Roon

    JM
    Dr. Jennifer Marti
    Breast Surgical Onc · Englewood Health

    Summary

    BACKGROUND: When a breast abnormality is palpated on a clinical breast exam in the setting of negative imaging (mammography and/or sonography), fine-needle aspiration (FNA) or magnetic resonance imaging (MRI) often is performed as part of the "triple test" to rule out malignancy. Because the negative predictive value (>97 %) of modern breast imaging is high, we hypothesized that additional evaluation with FNA and MRI adds little diagnostic value.METHODS: This study queried institutional databases to identify patients with negative breast imaging who underwent MRI or FNA for evaluation of a palpable breast abnormality on a clinical breast exam (2009-2023).RESULTS: For 83 patients with 89 palpable abnormalities, the mean age was 48 years (interquartile range [IQR], 22.75 years). Two (2.4 %) of the patients had concurrent breast cancer. Of the 89 masses, 67 (75.3 %) underwent FNA only, 19 (21.3 %) underwent MRI only, and 3 (3.4 %) underwent FNA and MRI. The FNA findings were benign in 42 (60 %) cases, nondiagnostic in 25 (35.7 %) cases, atypical in 3 (4.3 %) cases, and malignant in 0 % cases. All MRIs were negative for an imaging correlate. For 12 masses, surgery was performed (11 excisional biopsies, 1 incisional biopsy), and all surgical pathology results were benign. During a median follow-up period of 6.6 years, no patients developed malignancy at the site of palpable abnormality, and six patients (7.2 %) developed breast cancer at other sites.CONCLUSIONS: For women with palpable abnormalities and negative imaging, upgrade to malignancy with FNA or MRI was 0 %. We concluded that FNA or MRI as part of the "triple test" is a low-value intervention. Patients with a palpable breast abnormality may be safely followed with interval imaging.
    JMDr. Jennifer Marti

    Dr. Jennifer Marti

    Surgery · Breast Surgical Oncology
    Englewood Health
    jenniferm